Compared with the anti‐ACE2‐IgM‐negative group, patients with anti‐ACE2 IgM antibodies were more likely to receive pulse dose methylprednisolone (80% vs 30%, P = 0.043) and showed a trend toward higher prevalence of synovitis (100% vs 51%, P = 0.059) and worse FVC (median FVC percentage predicted 59% [interquartile range (IQR) 58‐61] vs 78% [IQR 63‐93], P = 0.056) (Table 1). This evidence concerns the gene ACE2 and synovitis.